Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease
Aim. To investigate the clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease (CHD). Subjects and methods. Fifty patients aged 40-75 years with asthma concurrent with CHD were examined. External respiratory function (ERF),...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2015-09-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/view/31806 |
| _version_ | 1819171646210048000 |
|---|---|
| author | O V Byelan O A Borzykh T V Mamontova I P Kaidashev |
| author_facet | O V Byelan O A Borzykh T V Mamontova I P Kaidashev |
| author_sort | O V Byelan |
| collection | DOAJ |
| description | Aim. To investigate the clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease (CHD). Subjects and methods. Fifty patients aged 40-75 years with asthma concurrent with CHD were examined. External respiratory function (ERF), electrocardiograms, blood pressure (BP), and anthropometric measurements were assessed in all the patients. Blood and urine laboratory values and high-sensitivity C-reactive protein (hs-CRP) concentrations were estimated; endothelial function was determined measuring endothelium-dependent and endothelium-independent vasodilation (EDVD and EIVD). The patients were randomized into a comparison group receiving only standard therapy and a study group taking pioglitazone as part of combination therapy for 3 months. Results. At the randomization stage prior to pioglitazone combination therapy, the patient groups did not statistically significantly differ in basic clinical and anamnestic data. Three-month standard therapy resulted in stabilization of ERF and endothelial function. During the treatment, there were increases in the frequency of asthma symptoms and the duration of angina attacks, however, there was a decline in hs-CRP levels (p |
| first_indexed | 2024-12-22T19:54:36Z |
| format | Article |
| id | doaj.art-b273ec2e813644c8b66e51fc2bb5ffea |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-12-22T19:54:36Z |
| publishDate | 2015-09-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-b273ec2e813644c8b66e51fc2bb5ffea2022-12-21T18:14:28Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422015-09-01879445128822Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart diseaseO V ByelanO A BorzykhT V MamontovaI P KaidashevAim. To investigate the clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease (CHD). Subjects and methods. Fifty patients aged 40-75 years with asthma concurrent with CHD were examined. External respiratory function (ERF), electrocardiograms, blood pressure (BP), and anthropometric measurements were assessed in all the patients. Blood and urine laboratory values and high-sensitivity C-reactive protein (hs-CRP) concentrations were estimated; endothelial function was determined measuring endothelium-dependent and endothelium-independent vasodilation (EDVD and EIVD). The patients were randomized into a comparison group receiving only standard therapy and a study group taking pioglitazone as part of combination therapy for 3 months. Results. At the randomization stage prior to pioglitazone combination therapy, the patient groups did not statistically significantly differ in basic clinical and anamnestic data. Three-month standard therapy resulted in stabilization of ERF and endothelial function. During the treatment, there were increases in the frequency of asthma symptoms and the duration of angina attacks, however, there was a decline in hs-CRP levels (phttps://ter-arkhiv.ru/0040-3660/article/view/31806asthmacoronary heart diseasepioglitazonesystemic inflammationendothelial dysfunction |
| spellingShingle | O V Byelan O A Borzykh T V Mamontova I P Kaidashev Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease Терапевтический архив asthma coronary heart disease pioglitazone systemic inflammation endothelial dysfunction |
| title | Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease |
| title_full | Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease |
| title_fullStr | Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease |
| title_full_unstemmed | Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease |
| title_short | Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease |
| title_sort | clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease |
| topic | asthma coronary heart disease pioglitazone systemic inflammation endothelial dysfunction |
| url | https://ter-arkhiv.ru/0040-3660/article/view/31806 |
| work_keys_str_mv | AT ovbyelan clinicaleffectivenessofpioglitazoneinthecombinationtreatmentofpatientswithasthmaconcurrentwithcoronaryheartdisease AT oaborzykh clinicaleffectivenessofpioglitazoneinthecombinationtreatmentofpatientswithasthmaconcurrentwithcoronaryheartdisease AT tvmamontova clinicaleffectivenessofpioglitazoneinthecombinationtreatmentofpatientswithasthmaconcurrentwithcoronaryheartdisease AT ipkaidashev clinicaleffectivenessofpioglitazoneinthecombinationtreatmentofpatientswithasthmaconcurrentwithcoronaryheartdisease |